{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:37:19Z","timestamp":1787240239539,"version":"build-2736575974"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cervical cancer screening through cytology and human papillomavirus (HPV) testing is essential for early detection of precancerous lesions, yet long-term institutional data integrating cytological trends, HPV genotype epidemiology, and diagnostic performance from Turkey remain limited. This study aimed to analyze the distribution and temporal trends of cervical cytological abnormalities, HPV prevalence and genotype distribution, and cytology-histopathology concordance over a 12-year period at a tertiary care center in Istanbul.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis of all cervical smear samples collected between January 2014 and December 2025 was conducted. Cytology results were classified according to the Bethesda 2014 system. HPV testing, which was performed on a subset of the study population based on clinical indications and kit availability, included mRNA-based assay (Aptima, 2020\u20132021,\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f4,648) and DNA genotyping (2024\u20132025,\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f4,308). Cytology-histopathology correlation was assessed for cases with biopsy within 180\u202fdays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 83,148 cervical smear records, 76,232 evaluable results from women aged \u226521\u202fyears were included. The overall epithelial cell abnormality rate was 7.93%, with atypical squamous cells of undetermined significance (5.83%) and low-grade squamous intraepithelial lesions (1.77%) being the most common findings. Epithelial cell abnormality rates varied significantly across age groups, with the highest rate in the 18\u201320 age group (12.78%) and a significant inverse correlation with increasing age (\n                      <jats:italic>r<\/jats:italic>\n                      \u202f=\u202f\u22120.955,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). Among tested patients, HPV positivity was 9.1% by mRNA testing and 9.9% by DNA genotyping, with HPV-16 predominating in both methods (20.5 and 32.8% of positive cases, respectively). Notably, HPV-56 (16.6%) and HPV-51 (14.3%) were more prevalent than HPV-18 (8.9%). High-grade squamous intraepithelial lesion cytology demonstrated a positive predictive value of 89.2% for detecting cervical intraepithelial neoplasia grade 2 or higher. A significant decrease in epithelial cell abnormality rates was observed over the study period (\n                      <jats:italic>r<\/jats:italic>\n                      \u202f=\u202f\u22120.591,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.043), with a more pronounced decline in high-grade abnormalities (\n                      <jats:italic>r<\/jats:italic>\n                      \u202f=\u202f\u22120.911,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The 12-year analysis shows a decrease in cervical cytological abnormalities and provides valuable epidemiological data on HPV genotype distribution in a Turkish population. The high prevalence of non-vaccine-targeted genotypes, such as HPV-56 and HPV-51, should be considered in future vaccination strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1818289","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:37:05Z","timestamp":1777354625000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Twelve-year trends in cervical cytology screening: a retrospective analysis of 83,148 smears from a Turkish tertiary care center"],"prefix":"10.3389","volume":"14","author":[{"given":"Berivan","family":"Guzelbag","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Haseki Training and Research Hospital, University of Health Sciences","place":["Istanbul, T\u00fcrkiye"]},{"name":"Department of Molecular and Medical Genetics, Institute of Graduate Studies, Biruni University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen Gul","family":"Uzuner","sequence":"additional","affiliation":[{"name":"Department of Pathology, Haseki Training and Research Hospital, University of Health Sciences","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melik","family":"Selcuk","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Haseki Training and Research Hospital, University of Health Sciences","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ermin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Haseki Training and Research Hospital, University of Health Sciences","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagseli Goksu","family":"Ozgun Selcuk","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Haseki Training and Research Hospital, University of Health Sciences","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Numan","family":"Cim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Haseki Training and Research Hospital, University of Health Sciences","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical Cancer elimination initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e055470","DOI":"10.1136\/bmjopen-2021-055470","article-title":"Global trends and age-specific incidence and mortality of cervical cancer from 1990 to 2019: an international comparative study based on the global burden of disease","volume":"12","author":"Yang","year":"2022","journal-title":"BMJ Open"},{"key":"ref5","volume-title":"Global strategy to accelerate the elimination of cervical cancer as a public health problem","year":"2020"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2","author":"Zur Hausen","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(sici)1096-9896(199909)189:1<>3.0.co;2-f","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"ref8","first-page":"1","article-title":"IARC Monogr Eval Carcinog risks hum","year":"2012"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature","volume":"404","author":"Wei","year":"2024","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","article-title":"Carcinogenic human papillomavirus infection","volume":"2","author":"Schiffman","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1002\/ijc.31212","article-title":"Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women","volume":"142","author":"Gultekin","year":"2018","journal-title":"Int J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.pvr.2019.03.002","article-title":"Mega Hpv laboratories for cervical cancer control: challenges and recommendations from a case study of Turkey","volume":"7","author":"Gultekin","year":"2019","journal-title":"Papillomavirus Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e52615","DOI":"10.7759\/cureus.52615","article-title":"Human papillomavirus infection (HPV) prevalence in the Black Sea region of Turkey: primary HPV screening for cervical Cancer","volume":"16","author":"Dura","year":"2024","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/joc.joc_129_22","article-title":"High-risk human papillomavirus (hrHPV) prevalence and genotype distribution among Turkish women","volume":"40","author":"Gecer","year":"2023","journal-title":"J Cytol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMsr2030640","article-title":"The IARC perspective on cervical Cancer screening","volume":"385","author":"Bouvard","year":"2021","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/cncy.21521","article-title":"The pap test and Bethesda 2014","volume":"123","author":"Nayar","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/s0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3322\/caac.21628","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society","volume":"70","author":"Fontham","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(22)00294-7","article-title":"Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis","volume":"23","author":"Arbyn","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e1115","DOI":"10.1016\/S2214-109X(22)00241-8","article-title":"Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis","volume":"10","author":"Bruni","year":"2022","journal-title":"Lancet Glob Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ijgo.2009.04.003","article-title":"Prevalence of cervical cytological abnormalities in Turkey","volume":"106","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1001\/jama.285.11.1500","article-title":"Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL triage study","volume":"285","author":"Stoler","year":"2001","journal-title":"JAMA"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00404-012-2280-z","article-title":"Detection and genotyping of cervical HPV with simultaneous cervical cytology in Turkish women: a hospital-based study","volume":"286","author":"Yuce","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical Cancer screening tests and Cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3855\/jidc.14663","article-title":"Human papillomavirus prevalence and genotype distribution in cervical swab samples in Istanbul, Turkey","volume":"15","author":"Alacam","year":"2021","journal-title":"J Infect Dev Ctries"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1002\/jmv.27921","article-title":"The prevalence and distribution of human papillomavirus in 4267 Turkish women with or without cervical lesions: a hospital-based study","volume":"94","author":"Altay-Kocak","year":"2022","journal-title":"J Med Virol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5146\/tjpath.2013.01188","article-title":"HPV types in Turkey: multicenter hospital based evaluation of 6388 patients in Turkish gynecologic oncology group centers","volume":"29","author":"Dursun","year":"2013","journal-title":"Turk Patoloji Derg"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/01.AOG.0000296488.85807.b3","article-title":"Liquid compared with conventional cervical cytology: a systematic review and meta-analysis","volume":"111","author":"Arbyn","year":"2008","journal-title":"Obstet Gynecol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ijgo.2015.07.024","article-title":"Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy","volume":"132","author":"Mustafa","year":"2016","journal-title":"Int J Gynaecol Obstet"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1097\/LGT.0b013e318285423c","article-title":"Benchmarking CIN 3+ risk as the basis for incorporating HPV and pap cotesting into cervical screening and management guidelines","volume":"17","author":"Katki","year":"2013","journal-title":"J Low Genit Tract Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/AOG.0b013e31818f5008","article-title":"Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2","volume":"113","author":"Castle","year":"2009","journal-title":"Obstet Gynecol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1097\/AOG.0b013e3181fe777f","article-title":"Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women","volume":"116","author":"Moscicki","year":"2010","journal-title":"Obstet Gynecol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ijc.21955","article-title":"Overview of the European and north American studies on HPV testing in primary cervical cancer screening","volume":"119","author":"Cuzick","year":"2006","journal-title":"Int J Cancer"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1309\/AJCPZ5JY6FCVNMOT","article-title":"High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study","volume":"135","author":"Stoler","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/LGT.0000000000000528","article-title":"2019 ASCCP risk-based management consensus guidelines: methods for risk estimation, recommended management, and validation","volume":"24","author":"Cheung","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"ref40","article-title":"Turkey: Human Papillomavirus and Related Cancers, Fact Sheet 2023: ICO\/IARC HPV Information Centre","year":"2023"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/nejmoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"100401","DOI":"10.1016\/j.eclinm.2020.100401","article-title":"Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries","volume":"23","author":"Kjaer","year":"2020","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1818289\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:37:06Z","timestamp":1777354626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1818289\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":43,"alternative-id":["10.3389\/fpubh.2026.1818289"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1818289","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1818289"}}